Treatments – PULMONARY HYPERTENSION

Economic and Social Burden of Pulmonary Arterial Hypertension in Italy: A Cost-of-Illness Study, Drugs Real World Outcomes, October 17, 2025

A paper titled “Economic and Social Burden of Pulmonary Arterial Hypertension in Italy: A Cost-of-Illness Study” was recently pubclished in Drugs Real World Outcomes journal. The aim of the authors was to estimate the economic and social burden of pulmonary arterial hypertension (PAH) in Italy, including direct healthcare costs, direct non-healthcare costs, and indirect costs […]

Economic and Social Burden of Pulmonary Arterial Hypertension in Italy: A Cost-of-Illness Study, Drugs Real World Outcomes, October 17, 2025 Read Post »

Pulmonary arterial hypertension (PAH): sex-specific differences and outcomes, Therapeutic Advances in Respiratory Disease, Jan-Dec 2025

Pulmonary arterial hypertension has a higher prevalence in women than men, yet notable sex-based differences influence disease presentation, treatment response, and outcomes. Based on data from major pulmonary arterial hypertension clinical trials the authors of a recent study published in Therapeutic Advances in Respiratory Disease have found that: These sex-based differences, say the authors, highlight

Pulmonary arterial hypertension (PAH): sex-specific differences and outcomes, Therapeutic Advances in Respiratory Disease, Jan-Dec 2025 Read Post »

Societal Costs Associated With Pulmonary Arterial Hypertension Subgroups: A Study Utilizing Linked National Registries, Pulmonary Circulation, April 17, 2025

Pulmonary arterial hypertension (PAH) represents a significant economic burden on society, as revealed by a comprehensive Swedish study published on Pulmonary Circulation on April 17, 2025, examining the societal costs associated with this condition. The research tracked patients across various pulmonary arterial hypertension subgroups—idiopathic/hereditary pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue disease,

Societal Costs Associated With Pulmonary Arterial Hypertension Subgroups: A Study Utilizing Linked National Registries, Pulmonary Circulation, April 17, 2025 Read Post »

Full transcripts of the Alliance for Pulmonary Hypertension’s 2023 webinars now available for in a format that can be translated into 40 languages

The full transcripts of the Alliance for Pulmonary Hypertension’s 2023 six webinars are now available! The transcripts encapsulate invaluable insights that continue to resonate with current trends and emerging issues, serving as a vital resource for our community. They are now in a format that can be translated into 40 languages, thanks to the embedded

Full transcripts of the Alliance for Pulmonary Hypertension’s 2023 webinars now available for in a format that can be translated into 40 languages Read Post »

Wrapping up a successful year of pulmonary hypertension knowledge-sharing educational live web events!

The Alliance for Pulmonary Hypertension has just held the last webinar of the six-part series it launched in June 2023 exploring the innovations outlined in the 2022 joint clinical guidelines on pulmonary hypertension by the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Across these six insightful sessions, we delved into pivotal

Wrapping up a successful year of pulmonary hypertension knowledge-sharing educational live web events! Read Post »

The “Pulmonary Hypertension Global Patient and Carer Survey” (PH GPS) is launched, October 16, 2023

This survey, the first of its kind, has been designed to help improve global understandings of how pulmonary hypertension affects the lives of patients and in what ways pulmonary hypertension care needs to be improved. The survey has been written by a multidisciplinary panel of pulmonary hypertension specialists and patient group advocates from the pulmonary

The “Pulmonary Hypertension Global Patient and Carer Survey” (PH GPS) is launched, October 16, 2023 Read Post »

Sunday “mixing parties”: a husband’s creative way to prepare his wife’s pulmonary hypertension medications to the beat of their favorite tunes!

Micheal Garrett is a pulmonary hypertension caregiver from Humble in Texas, USA. He is a caregiver for his wife, who is 42, and was diagnosed in December 2017 with pulmonary arterial hypertension. Along with her pulmonary arterial hypertension diagnosis, she was also diagnosed with Lupus. She is on intravenous therapy with Veletri (epoprostenol). Michael started

Sunday “mixing parties”: a husband’s creative way to prepare his wife’s pulmonary hypertension medications to the beat of their favorite tunes! Read Post »

Lay summary of the 2022 ESC/ERS clinical guidelines on the diagnosis and treatment of pulmonary hypertension now available in 11 languages!

“Diagnosing and treating pulmonary hypertension – understanding the professional guidelines” is an easy to understand summary of the joint European Society of Cardiology (ESC) and European Respiratory Society (ERS) clinical guidelines for pulmonary hypertension (PH). It was published on the European Lung Foundation (ELF) website on 02/11/2022. It is for people with pulmonary hypertension, or

Lay summary of the 2022 ESC/ERS clinical guidelines on the diagnosis and treatment of pulmonary hypertension now available in 11 languages! Read Post »

PHA UK’s “sister” website, phocusonlifestyle.org, is addressed at patients and caregivers and houses a wealth of support resources and pulmonary hypertension patient stories

http://www.phocusonlifestyle.org is the “sister” website to that of the UK Pulmonary Hypertension, PHA UK. It is aimed at patients and peers supporting each other through stories. It also houses written resources covering a very wide range of issues related to living with pulmonary hypertension including:

PHA UK’s “sister” website, phocusonlifestyle.org, is addressed at patients and caregivers and houses a wealth of support resources and pulmonary hypertension patient stories Read Post »

The 2022 “Clinical Guidelines for the diagnosis and treatment of pulmonary hypertension” by the European Society of Cardiology (ESC) and European Respiratory Society (ERS)

The work of two years of the Task Force in charge of the new European Society of Cardiology (ESC) and European Respiratory Society (ERS) joint Clinical Guidelines for the diagnosis and treatment of pulmonary hypertension has finally come to an end. The new guidelines were officially presented yesterday at the ESC Annual Congress in Barcelona

The 2022 “Clinical Guidelines for the diagnosis and treatment of pulmonary hypertension” by the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Read Post »